Belite Bio, Inc
BLTE
주식 순위
#3148
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
주가
$143.80
마지막 동기화: 2026-10-16
시가총액
$5.74B
변동 (1일)
-5.78%
변동 (1년)
63.95%
국가
US
거래 Belite Bio, Inc (BLTE)
카테고리
Healthcare
Belite Bio, Inc (BLTE)의 EPS
June 2026 기준 EPS TTM: $-2.76
Belite Bio, Inc의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-2.76입니다. 2023년 말에는 회사의 EPS가 $-1.19였으며, 이는 2022년의 EPS $-0.63와 증가입니다.
Belite Bio, Inc의 EPS 기록 (2020 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $-2.76 | 133.90% |
| 2024 | $-1.18 | -0.84% |
| 2023 | $-1.19 | 88.89% |
| 2022 | $-0.63 | 57.50% |
| 2021 | $-0.40 | -35.48% |
| 2020 | $-0.62 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $17.32 | -727.54% |
US
|
|
| $-7.98 | 189.13% |
US
|
|
| $-5.29 | 91.67% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,105.07% |
NL
|
